Abstract
Fetal hemoglobin (HbF) is the major genetic modulator of the hematologic and clinical features of sickle cell disease, an effect mediated by its exclusion from the sickle hemoglobin polymer. Fetal hemoglobin genes are genetically regulated and the level of HbF and its distribution among sickle erythrocytes is highly variable. Some patients with sickle cell disease have exceptionally high levels of HbF that are associated with the Senegal and Saudi-Indian haplotype of the HBB-like gene cluster; some patients with different haplotypes can have similarly high HbF. In these patients, high HbF is associated with generally milder but not asymptomatic disease. Studying these individuals might provide additional insights into HbF gene regulation. HbF appears to benefit some complications of disease more than others. This might be related to the premature destruction of erythrocytes that do not contain HbF, even though the total HbF concentration is high. Recent insights into HbF regulation have spurred new efforts to induce high HbF levels in sickle cell disease beyond those achievable with the current limited repertory of HbF inducers.
Fetal Hemoglobin in Sickle Cell Anemia
Appreciating the role of fetal hemoglobin (HbF;∝2γ2) in sickle cell disease started more than 60 years ago when Janet Watson confirmed that infants with sickle cell disease had few symptoms and that their deoxygenated erythrocytes took longer to sickle and did not deform as extensively as did their sickle cell trait-carrying mother's cells. She attributed these observations to high HbF levels in infant blood. Sickle hemoglobin (HbS) gelation studies showed that HbF did not interact with HbS; it was also reported that compound heterozygotes for sickle cell trait and hereditary persistence of HbF (HPFH) were clinically normal despite having a very high HbS concentration. (reviewed in 1 ) HbF is the most powerful modulator of the clinical and hematologic features of sickle cell anemia (defined as homozygosity for glu6val in the β -globin gene or HBB). To protect against various complications of disease, different concentrations of HbF were postulated to be required, although any increment in HbF had a beneficial effect on mortality. 2, 3 Higher HbF levels were associated with a reduced rate of acute painful episodes, fewer leg ulcers, less osteonecrosis, less frequent acute chest syndromes and reduced disease severity. However, HbF level had a weak or no clear association with priapism, urine albumin excretion, stroke and silent cerebral infarction, systemic blood pressure and perhaps sickle vasculopathy as estimated by tricuspid regurgitant velocity (reviewed in 4 ). The failure of HbF to modulate uniformly all complications of sickle cell disease might be related to the pathophysiological events that impact the likelihood of developing these complications. Many epidemiological studies suggested that disease complications most closely linked to sickle vasoocclusion and blood viscosity were robustly related to HbF concentration while complications associated with the intensity of hemolysis were less affected 5 (and references therein) although HbF is protective for leg ulcers, one complication closely associated with hyper-hemolysis. 6, 7 After defining hyper-hemolysis by the highest quartile of serum lactic dehydrogenase and controlling for liver disease by examining only patients with normal serum alanine aminotransferase, HbF
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From 4 levels were lower in patients with the highest quartile compared with the lowest quartile of hemolysis. 8 Even when total HbF levels are high, perhaps the intravascular hemolysis of erythrocytes containing little or no HbF leads to sufficient nitric oxide (NO) scavenging by plasma hemoglobin to provoke hemolysis-related complications. 9 ( Fig. 1 Recent studies that sequenced about 87 kb within the HBB gene-like cluster suggested that a SNP in LD with rs7482144, (rs10128556; p=1.2E-09), was more strongly associated with HbF than rs7482144 (p=3.7E-07), however the effect (beta coefficients) of the 2 SNPs on HbF was very similar and the stronger p-value may be due to the higher minor allele frequency of rs10128556. Also, rs10128556 had an effect on HbF independent of rs7482144 (p = 0.047) and rs7482144 had no effect on HbF independent of rs10128556 (p = 0.78). 36 However, this determination was based on conditional haplotype tests that excluded uninformative haplotypes.
The test excluded less than 10% of the data for rs10128556 but nearly 90% for rs7482144 which severely affected its power and is reflected by the non-significant p-value for rs7482144.
The mechanism whereby this region influences HbF is unclear.
Homozygotes for the Saudi-Indian haplotype, which also includes rs7482144, have HbF levels substantially higher than homozygotes for the Senegal haplotype. 37 These observations suggest that other elements, perhaps linked to these haplotypes are differentially effecting HBG2 transcription. While it is likely that the association of a haplotype with the clinical features of sickle cell anemia is mediated by haplotype-related differences in HbF concentration, in nearly all instances the actual functional elements responsible for HbF modulation are unknown.
QTL modulating HbF
HbF levels are hereditable. 
F-cell production locus
A putative F-cell production locus was localized between DXS143 and DXS16 within Xp22.3-22.2 and hypothesized to account, in part, for the higher HbF levels in females compared with males, an observation found in both the normal population and in patients with sickle cell anemia. 64, 65 GWAS have yet to find a gene or polymorphism in the F-cell production locus at Xp22, the phenotype of which was associated with HbF in sickle cell anemia; probing this region with haplotype-tagging SNPs did not reveal a strong candidate gene. 59 Other genetic loci as modulators of HbF have been proposed but are less well established.
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Sickle Cell Disease and Unusually High HbF
HbF in African Americans
We define a "HbSF" phenotype as a HbF concentration of at least 10% in sickle cell anemia patients aged 4 years or more, the time by which HbF levels stabilize. 2010;116(21):858.). BCL11A rs766432 and HMIP rs9399137 had a higher minor allele frequency in patients with "high" HbF in both data sets and accounted for 20% of HbF variance.
The aforementioned 3 bp (TAC) in the HBS1L-MYB intergenic region was present in 18% of total chromosomes in the "high" HbF group, compared with a 3% frequency in the "low" HbF controls and was in complete linkage disequilibrium with rs9399137.
A 14.1 kb DNA fragment between HBG1 and HBD was sequenced in 15 "high" and 15
"low" HbF patients. This fragment included the 7.2 kb Corfu deletion that was associated with elevated HbF levels and contains binding sites for BCL11A. 69, 70 Four SNPs had significant frequency differences between "high" and "low" HbF groups (Fig 2A) . Three of the SNPs were between positions 49213 and 49994 and 1 was at position 54541. In silico analysis showed that the G-A polymorphism at position 49876 (rs968856) created a C/EBP binding site which is not present in the minor allele. The G-A polymorphism at position 49994 (rs968857) eliminated an AP-1 and NF-E2 binding sites, which are present in the minor alleles. Any functional significance of these SNPs remains to be explored ( Fig. 2A) .
HbF in Saudi Arabian sickle cell anemia
Sickle cell anemia in Saudi Arabia has population concentrations in the Southwestern 
Southwestern Province
The HbS gene in Saudi patients from the Southwestern Province was introduced from Africa and is present on typical African HBB haplotypes. Nevertheless, patients differ from African Americans phenotypically and have fewer episodes of stroke, priapism, and leg ulcers and a higher prevalence of splenomegaly.
14,71-73 This might be related to differences in HbF levels or co-inheritance of α thalassemia.
To examine genetic modifiers of HbF level in patients from the Southwestern Province, the 3 HbF QTLs were genotyped in 77 patients, aged 17.7±10 years, 69% with sickle cell anemia and 31% with HbS-β 0 thalassemia. 74 The distribution of HBB gene cluster haplotypes was; have regulatory roles in globin gene expression when examined in silico.
Eastern Province
Deep sequencing of more than 800 kb of DNA in all three major HbF QTLs has been completed. The results of these studies might uncover variants in Eastern Province sickle cell anemia patients that could be associated with their unusually high HbF level and be candidates for functional and mechanistic studies. 
HbS-HPFH

Genetic causes of high
Point mutations in HBG promoters
Point mutations associated with non-deletional HPFH were found in three regions 
HbS-Gene deletion HPFH
At least 8 HPFH-causing deletions within the HBB gene-like cluster of 10 to more than 80 kb have been described. They are associated with HbF levels of 20-30% that is distributed A form of deletion HPFH has been described in association with Hb Kenya, an abnormal hemoglobin resulting from a ~22.5 kb deletion leading to a fusion product composed of the HBG1 and HBB. HbS-Hb Kenya compound heterozygotes had mild microcytic anemia and an average of 10% HbF in a pancellular distribution. These patients had few, if any, sickle cellrelated events. HbF and Hb Kenya make up 30% or more of the total hemoglobin and this might be sufficient to inhibit sickling. known The average increment in HbF achieved in the MSH was only 3.6% over the baseline level of 5.1% but other studies using different dosing regimens found higher increases in HbF. [81] [82] [83] Long-term follow-up studies of MSH patients suggested that mortality was reduced in patients who took this drug and that side effects were minimal 83-86 ; other studies confirmed the benefits of hydroxyurea. 86 A trial of hydroxyurea in babies has been completed (NCT00006400). Although the trial's primary endpoints of preservation of renal and splenic function were not met during the relatively brief observation period, treated patients had less pain, higher hemoglobin concentrations, increased HbF and reduced leukocyte counts, with minimal short-term toxicity. 
Experimental HbF inducing agents
Not all patients respond to hydroxyurea and the erythrocytic distribution of HbF in treated patients is heterocellular. 88 Among responders, the increment in HbF is variable suggesting the need for additional agents capable of inducing HbF and perhaps broadening its cellular distribution. One class of promising agents are histone deacetylase (HDAC) inhibitors whose inhibition is associated with increased expression of HBG. Arginine butyrate, a short chain fatty acid with HDAC inhibitory activity used as single agent or with hydroxyurea has been associated with increases in HbF. 89, 90 However, a pulsed, or intermittent, dosing regimen was necessary to avoid cytotoxicity from butyrate while retaining the targeted promoter activation. Another oral short chain fatty acid derivative, sodium 2,2 dimethylbutyrate showed HbF induction in thalassemia in early phase clinical trials (NCT00842088). Suberoylanilide hydroxaminc acid (Vorinostat), an orally available agent approved for treatment of cutaneous T-cell lymphoma is an HDAC inhibitor that induced HbF expression in K562 cells. 91 A Phase1/2 trial of this agent in sickle cell anemia is presently enrolling patients (NCT01000155).
For
High throughput screening studies with follow-up of promising candidates have suggested that strong inhibitors of HDAC1 and HDAC2 were associated with substantial increments in both HBG expression and HbF in vitro. 92 BCL11A has been shown to interact with HDAC1 and HDAC2. 93 Decitabine (5-aza-2'-deoxycytidine), a less toxic and perhaps non-carcinogenic deoxynucleotide is also associated with DNA hypomethylation and has been used as single agent therapy and with hydroxyurea in a small number of patients with sickle cell anemia but Phase 2 or 3 studies have not been done. 94 The recent studies of BCL11A and HMIP have stimulated a search for new agents that might act by modulating the expression of these genes and their signaling pathways to augment
HbF expression in the β hemoglobinopathies.
95
Conclusion
HbF has beneficial effects in sickle cell anemia. The contrast between asymptomatic individuals HbS-gene deletion HPFH and symptomatic patients with sickle cell anemia with similarly high HbF levels suggests that if it were possible to induce high HbF levels in most sickle erythrocytes, and if this could be done before organ damage occurs, one might expect the disease to be "cured." Presently, this is not possible but a better understanding of how HbF levels are modulated might suggest new therapeutic approaches and combinations of HbFinducing agents that could allow this goal to be met. 
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